PROPANC BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PROPANC BIOPHARMA, INC. (PPCB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $72.51 thousand for the 12-month period ending 2022-06-30, per its 10-K filed 2023-09-28.
Discontinued › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-09-28
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-03-31 was $20.72K, a 0.00% change year-over-year.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-12-31 was $20.72K, a 0.00% change year-over-year.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-09-30 was $20.72K.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-03-31 was $20.72K, a 72.41% decline year-over-year.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $72.51K, a 12.50% decline from fiscal 2021.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $82.87K, a 72.41% decline from fiscal 2020.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $300.42K, a 625.01% increase from fiscal 2019.
- PROPANC BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $41.44K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2022-06-30 | $72.51K 10-K · filed 2023-09-28 | |||
| 2022-03-31 | $20.72K 10-Q · filed 2022-05-16 | $41.44K derived: sum of 2 quarters · filed 2023-05-15 | $62.15K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $20.72K 10-Q · filed 2023-05-15 | $41.44K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-09-30 | $20.72K 10-Q · filed 2023-05-15 | |||
| 2021-06-30 | $82.87K 10-K · filed 2022-09-28 | |||
| 2021-03-31 | $20.72K 10-Q · filed 2022-05-16 | $41.44K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $20.72K 10-Q · filed 2022-05-16 | |||
| 2020-06-30 | $300.42K 10-K · filed 2021-09-28 | |||
| 2020-03-31 | $75.10K 10-Q · filed 2021-05-14 | $150.21K derived: sum of 2 quarters · filed 2021-05-14 | $225.31K derived: sum of 3 quarters · filed 2021-05-14 | |
| 2019-12-31 | $75.10K 10-Q · filed 2021-05-14 | $150.21K derived: sum of 2 quarters · filed 2021-05-14 | ||
| 2019-09-30 | $75.10K 10-Q · filed 2021-05-14 | |||
| 2019-06-30 | $41.44K 10-K · filed 2020-10-01 | |||
| 2013-06-30 | $48.00K 10-K · filed 2014-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |